VTYX pre market gainer with good potentialTrading at 2.80 range right now. I see potential to 4-5 range, downside to 2.40. Again it is a bit too early prediction, so adjust your position size accordingly.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.79USD
−192.96 MUSD
0.00USD
54.69 M
About Ventyx Biosciences, Inc.
Sector
Industry
CEO
Raju S. Mohan
Website
Headquarters
San Diego
Founded
2018
FIGI
BBG00VC84K29
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
VTYX- a risky biotechnology penny stock LONGVTRX is on a 120 minute chart, currently trading at 90% off its ATH and 50% above its absolute
long term support level. Price tried to cross above the long term mean VWAP 3 months ago
but was rejected. I anticipate that in time it will try to so so again. From 3.3 to a target of 9
would be a mo
VTYX- Buy the Pullback after a massive Bullish Surge LONGVTYX is an illustrative case in the trend is your friend. VTTX warmed up on Frbruary 20th and
went parabolic on the next day and then faded while the moving averages and VWAP lines
caught up. This is a buyable dip. It has now printed a couple of engulfing bullish candles. VTYX
did less than
VTYX falls to support on private offering Biotech LONGVTYX- Ventyx Biosciences, Inc. (“Ventyx”), a clinical-stage biopharmaceutical company focused
on advancing novel oral therapies that address a range of inflammatory diseases with significant
unmet medical need, announced today that it has entered into a stock purchase agreement for
the sale of
VTYX - long - catalysts and gap - amazing R/RVentyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor
🟩 $VTYX - WATCHLISTThis is what we want to see from stocks and this is what real alpha looks like.
I want to see more and more names act like this one
$VTYX is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price today.
So I opened a long position from $19,95;
stop-loss — $1
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of VTYX is 2.15 USD — it hasn't changed in the past 24 hours. Watch Ventyx Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Ventyx Biosciences, Inc. stocks are traded under the ticker VTYX.
VTYX stock has fallen by −2.71% compared to the previous week, the month change is a 3.37% rise, over the last year Ventyx Biosciences, Inc. has showed a −85.53% decrease.
We've gathered analysts' opinions on Ventyx Biosciences, Inc. future price: according to them, VTYX price has a max estimate of 21.00 USD and a min estimate of 2.00 USD. Watch VTYX chart and read a more detailed Ventyx Biosciences, Inc. stock forecast: see what analysts think of Ventyx Biosciences, Inc. and suggest that you do with its stocks.
VTYX reached its all-time high on Mar 3, 2023 with the price of 47.25 USD, and its all-time low was 1.79 USD and was reached on Aug 22, 2024. View more price dynamics on VTYX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
VTYX stock is 4.29% volatile and has beta coefficient of 1.64. Track Ventyx Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Ventyx Biosciences, Inc. there?
Today Ventyx Biosciences, Inc. has the market capitalization of 151.94 M, it has increased by 0.91% over the last week.
Yes, you can track Ventyx Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Ventyx Biosciences, Inc. is going to release the next earnings report on Nov 8, 2024. Keep track of upcoming events with our Earnings Calendar.
VTYX earnings for the last quarter are −0.45 USD per share, whereas the estimation was −0.58 USD resulting in a 22.25% surprise. The estimated earnings for the next quarter are −0.52 USD per share. See more details about Ventyx Biosciences, Inc. earnings.
Ventyx Biosciences, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
VTYX net income for the last quarter is −31.95 M USD, while the quarter before that showed −38.57 M USD of net income which accounts for 17.17% change. Track more Ventyx Biosciences, Inc. financial stats to get the full picture.
No, VTYX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 80.00 employees. See our rating of the largest employees — is Ventyx Biosciences, Inc. on this list?
Like other stocks, VTYX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ventyx Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ventyx Biosciences, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ventyx Biosciences, Inc. stock shows the sell signal. See more of Ventyx Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.